China Medical System Holdings (CMS) and Incyte have entered into a collaboration and license agreement for the development and commercialisation of povorcitinib, a selective oral JAK1 inhibitor, to research, develop, register and commercialise the product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the Territory) and a non-exclusive license to manufacture the product in CMS’ Territory.
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Incyte`s oral Dupixent rival hits in midphase skin disease trial
Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
Incyte is rolling out more mid-stage data for its next-gen oral JAK inhibitor, this time in an indication where it’s recently scored an approval with another drug.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented today in a late-breaking oral presentation (Session: S042 – Late-Breaking Research: Session 2) at the 2023 American Academy of Dermatology (AAD) Annual Meeting, held from March 17-21 in New Orleans.
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa